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A conference was organised addressing a 
numher of questions on viral re-infection of 
the liver graft and their possihle answers. 
Presentations focused on the controversial 
indications for liver transplantation in 
hepatitis B virus (HBV)-related disorders 
due to the high rate of hepatitis B 
recurrence in the graft, to the selection of 
patients with hepatocellular carcinoma, to 
the prognosis of transplantation in hepatitis 
C virus (HCV) disorders and the role of 
HCV genotypes in determining the outcome 
of surgery, to the relatively favourahle 
outcome uf hepatitis D virus (HOV) 
transplants and of transplants with douhle 
HBV-HCV infection compared to HBV or 
HCV alone, to the role of immuno-
suppression in influencing the course of 
recurrent viral hepatitis. 
Dr. Umberto Cillo (Cattedra Malattie 
Apparato Digerente, Clinica Chirurgica I, 
Patologia Medica I, University of P,;dova) 
reported on behalf of the Pad ova liver 
transplant group (Patrizia Burra, Stefano 
Fagiuoli, Rosa Maria Iemmolo, Remo 
Naccarato) their experience on liver 
transplantation in HBV- and HCV- related 
cirrhosis and hepatocellular carcinoma. 
HBV,related cirrhosis 
As long-term passive immunoprophylaxis 
with anti-HBs immunoglobulins diminishes 
the rate uf HBV recurrence in transplanted 
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HBsAg +/HBV-ONA positive patients, 
candidates undergoing evaluation for liver 
transplantation in Padua were selected on 
the hasis of undetectahle serum HBV-DNA 
as assessed by polymerase chain reaction 
(PCR); at the time of liver transplantation, 
during the anhepatic phase, passive 
immunoprophylaxis with 10.000 IU anti-
HBs IG was given i.v. and the same dose was 
administered daily during the first 7 post-
operative days and weekly for 4 weeks after 
transplantation. The maintainance dose was 
1500 IU Lm. weekly to keep anti-HBs titre 
above 400 lUll. 
At the beginning of the transplant program, 
five patients were transplanted hefore the 
selection/immunoprophylaxis protocol was 
started; 4/5 developed HBV-related liver 
disease, 2/4 died of hepatic failure, 
confirming that morbidity and mortality are 
high in non-selected patients. 
In the first series of 17 patients enrolled in 
the study, 6 died within three months and 
the remaining 11 (all HBsAg+/HBV-ONA-
hy PCR prior to liver transplantation and all 
receiving passive immunoprophylaxis) were 
re-evaluated at 3,6, 12,24,36 months after 
transplantatilm. 
HBV-DNA was undetectahle in serum in all 
patients at months 3 and at month 6 it was 
undetectable hoth in serum and tissue; it 
hecame positive in one patient who also 
developeJ anti-HCV E"g~ not'o" HCV 
infection pllst-rransplantation). 
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At month ,6 of follow up all patients hut 
(lOe \Vere HBsAg- and HBV-DNAnegati\'C 
hy PCR in serum ard tisslIe, (\ lntirming th~lt 
a strict :;e lection lD~lsed on llnllctecLlh k 
HBV-DNA and long term imIllUl1l1pro-
phybxis are needed to manta in guod ,graft 
function and patient sun'i\'dl after tr~lt1s­
plantation, 
eCs~related cirrhosis 
The recurrence of HCV llisease is recognisell 
as a potential factor limiting hoth graft and 
recipient survival in [,atients undergoing 
liver transplantation for HCV-related 
cirrhosis, 
In Padua HCV-related cirrhosis was the 
indication for liver transplantation in ,6 
patients, equal to 29,8% llf the tptal of 127 
patients transplanted (29 males, 7 females, 
age 31-63 years). 
Anti-Hey, serum HCV-RNA activity and 
Knlldell score on li\'Cr hiopsy were assessed 
at 3, 6 and 12 munths after liver trans-
plantation. 
Hepatitis C recurred in 19 patients (52.7%) 
hetween ) and 6 munths after ltver trans-
plantation; chronic acttve hepatitis 
developed within 12 months in 9 patients 
and 1 fD~ltient died of liver failure 24 months 
after transplantatiun. HCV-RNA was found 
in 1 4! 2 7 t est e d pat i e n t s h efor e t ran s-
plantation; it was confirmell at each interval 
time after transphntarilln. 
Anti-HCV remained pllsitive in all patients 
~lfter the operation. 
In the HCV-RNA pllsitive suhgwup of 
patients, the mean Knodell score in liver 
hillpsies was 9.7±"5. By contrast, a 
recurrence of HCV disease occurred in 5 of 
the 13 patients who were HCV-RNA 
negative at transplantation; chronic active 
hepatitis at 12 months was seen in 2 who 
had hecome HCV-RNA positive 3 months 
after surger')'. The Knodell scure in liver 
hiopsies in these patients was significantly 
luwer cmnpared to HCV-RNA + patients 
().O± 1.4, 1'<0.001). 
The persistence of active viral replicatiun is 
rherefore associated with a more a,l:gressive 
cuurse of the recurrent hepatitis. In the 
medium term, graft loss llue ro HCV 
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recurrence is uncommon hut nwrhidity 
seems to increase with llln[!er follow-ups. 
Hepatocellular carcinoma 
The role of liver transplantation in the 
treatment uf hepatocelluLn carcinuma is 
controversial l'ecllIse the flsk uf tumour 
recurrence after the operation has not heen 
c1earlvestahlished. 
The ~bta llf 221 patients who underwent 
I inr tr,ll1spL1l1LHion hetween 1990 and 
1996 were reviewed. Hepatocellular 
carcinoma was present in 27 patients 
(12.2%); in 13, the tumour was found 
incidentally at the time of transplantation. 
The liver disease was HCV-related in l8 
patients, HBV-related in 4, alcoholic in 2, 
primary sclerosing cholangitis-related in 2. 
Two patients underwent liver trans-
plantation for primitive hepatocellular 
carcinoma. 
All 14 patients with hepatocellular 
carcinoma diagnosed hefore surgery received 
transarterial chemoemholisation (TACE) 6 
to 3 months hefore transplantation. Sixteen 
patients (11 llf 14 with dia[!nosed hepato-
cellular carcinoma and 5 of 13 with 
incidental hepatocellular carcinoma) 
underwent post-transplant chemopro-
phylaxis with 5-fluowuracil (5-FU) and 
carhop latin. Only one patient developed 
severe leucopenia requiring withdrawal of 
treatment. 
After a mean 27.9 months follow-up, the 
cumulative survival rate was 92.5 lX); two 
patients died within 4 weeks after trans-
plantation for surgical complications, one 
patient died three years later for recurrence 
of HBV cirrhosis with no recurrence of 
hepatocellular carcinoma. Only one patient 
who did not receive adjuvant chemotherapy 
developed hepatocellular carcinoma in the 
graft. 
Thus liver transplantation may he 
coosiJered an llption in well-selected 
patients with hepatocellular carcinoma; 
neoadjuvant TACE and post-transplantation 
chemoprophylaxis may help in limiting 
tumours after liver transplantation. 
Dr. T. Starzl argued that the stage of HCC 
at the time of transplantation is important, 
with) cm as the critical si:e of the HCC 
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nodule permitting "safe" transplantation; 
even more critical is a timely operation, 
since many such patients will he screening 
themselves out simply because they have 
developed metastasis if surgery is delayed. 
An exception are fibrolamellar hepatomas. 
These tumours may be separate and distinct; 
tumour size may not matter. Even with 
extra-hepatic metastases some patients have 
survived more then ten years, with 5 years 
survival at nearly 70%. Dr. Starzl stressed 
that transplantation may also offer a 
consistent salvage to patients with large or 
widespread tumours that by any current 
criteria would be considered hopeless. Thus 
ultimately it becomes a matter of applied 
ethics to withhold a therapy which would 
provide some kind of help even to the badly 
selected liver patient. Along this line Dr. 
D' Amico from Padua stressed that marginal 
livers are currently thrown away by the 
hundreds and that many more of them could 
be used for neoplastic patients, providing a 
larger therapeutic window for this un-
fortunate group. One example is duct cell 
carcinoma; although transplantation survival 
is only 30% at 5 years, this proportion of 
patients would have been doomed to death 
without operation. On this issue, Dr. Starzl 
commented that as a non-neoplastic patient 
he would rather have a whole liver from a 60 
year-old man than a split liver from a 20 
year-old donor, but as a neoplastic patient he 
would take any type of liver. 
Of course the use of marginal livers implies a 
commitment to re-transplantation if things 
go wrong; if not, no responsible surgeon and 
no patient would accept a marginal liver 
when they had a chance to wait for a good 
one from a healthy donor. 
Dr. Starzl reiterated that when the doctor 
operates he commits himself to that patient 
and not to some statistic and that patient 
abandonment is never possihle. 
Dr. Ignazio Marino in collaboration with 
Dr. T. Gayowski and N. Singh (National 
Liver Transplant Center, Dept. Yeterans 
Affairs, Pittsburgh, PA and the T. E. Starzl 
Transplantation Institute; Dept. of Surgery, 
University of Pittsburgh, PA) addressed the 
issue of the role of HCY genotypes in 
influencing the recurrence of hepatitis C 
after orthotopic liver transplant (OlT). 
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Between October 1989 and October 1995, 
140 othotopic liver transplantations were 
performed on 130 cnnsecutive patients, 
under primary tacrolimus-based immuno-
suppression. Fifty-three percent (68/130) of 
these patients underwent transplantation for 
endstage liver disease due to hepatitis C. 
The authors investigated the influence of 
HCY genotypes on the incidence and 
timing of recurrent HCY hepatitis, survival, 
infectious morbidity, and response to 
interferon-a therapy in this unique patient 
population. HCY genotype was determined 
by direct sequencing of the NS5 region of 
HCY and with type specific primers. 
Genotype 1 a (66%, 32/47) was the predo-
minant genotype. Type 1 b was found in 25% 
(12/47), and type 2b in 9% (4/47). Histo-
pathologically, recurrent Hey hepatitis 
developed in 53% (25/47), of the patients 
after liver transplantation. These included 
45% (14/31) of the patients with type la, 
67% (8/12) with type lb, and 25% 0/4) of 
the patients with type 2b (p>0.5). The time 
to recurrence and the severity of Hey 
recurrence as defined by aminotransferase 
levels or Knodell scores were not different 
between the 3 genotypes (Table 1). 
No variable differed significantly among the 
three groups 
There was a trend towards the higher 
incidence of major infections in patients 
with type 1b (75%) vs type 1a (48%), and 
type 2b (50%) (p=O.l1) (Table 2) (In 2b 
there was only one recurrence). 
The response to interferon-a therapy did not 
differ significantly between the genotypes. 
Mortality at 5 years was 16% (5/31) in 
patients with genotype la, 42% (5/12) in 1b, 
and 50% (2/4) in 2b (p=O.06). In 
conclusion, the incidence, time to 
recurrence, and response to interferon 
therapy did not differ between the various 
genotypes in liver transplant recipients. 
However, there was a trend towards higher 
morbidity and overall mortality in patients 
with genotype 1 b after transplantation. 
Dr. Giorgio Rossi, Institute of Experimental 
and Transplant Surgery, University of 
Milano, investigated the outcome of liver 
transp.lantation in HBY-Hey co-infected 
patients vs patients infected with HBV or 
Hey alone. Data were presented on viral 
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Table 1. Incidence. timing and severity of recurrent HCV in patients with 3 genotypes 
Variable 
I 
la (n=31) 
I 
lb (n=12) 
I 
2b(n=4) 
o~lte llf Recurrence -) l (l, ~ I(l 67% 2 FE~{F 
:Vkdi,m Time of 
Recurrence. tn days (range) )01 198 111 
(H7 -994) (72-174) 
Mean AST- 116 88 150 
MeanALT" 124 87 224 
Mean Knodell score 5.0 5.8 2 
• lL'IL, -:\ST. ul{lartatl', arnl1wtransg~raslD; ":\LT, ulan me urnmormmJcrasc 
infection in 138 transplants; 48 of them had 
HBY disease with or without delta co-
infection, 63 had Hey disease and 27 had 
double Hey and HBY disease (Figure 1), 
The Hey genotype (Table 3) was evaluated 
in a number of patients after the transplant. 
In patients with Hey infection genotype 1 b 
was more frequent (n = 23) compared to 
genotype 2 (n=13), Genotype Ib is 
widespread in Italy, is the most pathogenic 
and is the main indication for liver 
transplantation; type 2 is the second 
genotype in order of diffusion in Italy. 
However, in the groups with HBY-Hey co-
infection type 2 was more frequent than type 
1 h (n = 7 \'S n =4). Thus there was a different 
distrihution of genotypes in the 2 groups, 
although the difference was not statistically 
Table 2. Major infectionK~ ill patients with recurrent HCV 
significant. There were 3 RNA negative 
adult patients among the 16 patients (19%) 
in the HBY-Hey group and 4 (9%) RNA 
negative pediatric patients in the Hey 
group. The results are reported in Table 4. 
Survival in the HBY, Hey and HBY-Hey 
groups was respectively 65 0ft), 54% and 74%. 
No re-transplantation was required in the 
HBY-Hey group. 
The recurrence of the viral infection was 
diagnosed on the hasis of histology, 
elevation of liver enzymes and the finding of 
the HBsAg. 
In the group with HBY infection only, the 
rate of recurrence was 19(){); in the Hey 
group it was 50%. 
In the group with HBY-Hey cll-infection 
the rate of recurrence was 15% for HBY and 
I la (n=16) I lb (n=8) 
Major infection 50'){) 75% 
Mean number of infectiuns 1.0 1.67 
Major hacterial infectillns )8% 62'X, 
M'ljOf fungal infectillns 19% 0% 
CMV infecrion SO% 62% 
CMV disease 31% 25')\, 
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Liver Transplant Unit - Ospedale Maggiore, Milano 
o Viral cirrhosis 
• non-viral cirrhosis 
13850,2% 
13749,8% 
Figure 1. Liver transplantation for cirrhosis 
40% for HCY; these figures are not 
significantly different from the recurrence 
rate of each single infection. 
The fatality rate was 35%, 46% and 26% 
respectively, for the HBY, HCY and HBY-
HCY groups; no death was caused by viral 
recurrence in the HBY-HCY group while 
viral recurrence was the cause of death in 
11 % of the HBY fatalities and 35% of the 
HCY fatalities. Thus no patient died for 
viral-related disease recrudescence in the 
HBY-HCY group although the rate of viral 
recurrence was not different from the single 
infections; this probably indicates that HBY-
HCY re-infections run a milder clinical 
course than HBY or HCY infection alone. 
Possibly HBY and HCY interact so that 
their virulence is diminished, the clinical 
balance being a decreased damage to the 
liver graft. 
II HBV ± HOV 
DHCV 
• HBV + HCV 
4834,8% 
6345,rX, 
2719,6')10 
Dr. Mario Alessiani (lstituto di Patologia 
Chirurgica I, Universita-IRCCS, Policlinico 
San Matteo, Pavia) elaborated on the role of 
immunosuppression; this is a factor that can 
enhance liver disease recurrence both in 
hepatitis and in tumour patients. If 
immunosuppression were to be lowered, or, 
ideally, avoided, both groups would stand a 
distinctly smaller risk of disease recurrence. 
There are two main venues of research in 
this field: 
i. the first is the improvement of pharma-
cologic immunosuppression with better 
and more specific immunosuppressive 
drugs; 
ii. the second is the induction of better graft 
acceptance and the possibility to reach 
the final goal of graft tolerance without 
immunosuppression. 
Table 3. HBV-HCV co-infection vs HCV infection. Post-OLT HCV genotype infection 
HCV genotype 
la 
1b 
2 
3 
4 
RNA negative 
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I HBV-HCV (n=16) 
4 
7 
° 
3 
48 
I HCV (n=44) 
2 
23 
13 
4 
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Table 4. Results of OLT in viral cirrhosis 
Infection (#) I Alive I Re-OLT (%) I 
HBV±HDV 31 
( 48) (65%) ( 3 'X,) 
HCV 34 
(63 ) (54o,,{) ) ()%) 
HBV-HCV 20 0 
co-infection (74%) 
(27) 
At present one can count on an 
immunosuppressive armamentarium which 
is four times bigger than 10 years ago; 
however, the majority of the new immuno-
suppressive drugs are still under investi-
gation. In view of the wide choice of drugs, 
single and well defined immunosuppressive 
protocols should be used for all patients of 
transpl;mt centre; these should be much 
more flexible using different baseline agents 
on the basis of clinical parameters such as: 
• organ transplanted 
• type of rejection 
• primary or secondary disease 
• tolerance to drugs 
• age 
• cross-match 
An important parameter is the primary 
disease. Thus the first question is: which is 
at present the best primary baseline agent for 
hepatitis or tumour patients? In other words, 
is there a drug of choice that, without 
increasing the risk of rejection, can reduce 
the incidence and severity of disease 
recurrence? To date) the analysis can be 
performed only on two drugs considered as 
the main baseline agents: Cyclosporin A 
(CyA) and FK506. There is a lot of 
confusion on this subject in the literature, 
with claims in favour of CyA or in favour of 
FK506. There are reports in favour of CyA, 
but these studies contain biases, such as the 
small number of patients and the high 
dosage of FK506; in addition, a relationship 
between a higher incidence and severity of 
HCV recurrence and the use of FKS06 has 
not been demonstrated. Instead, in a recent 
US multi-centre randomised trial, the 
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Recurrence 
I Dead 
I Dead for 
(%) recurrence (%) 
6 17 , ~ 
(19%) (35%) (II '){) ) 
17 29 10 
(50%) (46'){) ) (35%) 
3 HBV (15%) 7 0 
8 HCV (40%) (26%) 
evaluation of 113 patients demonstrates that 
there is a trend to better survival at 3 years 
in the FK506 arm. 
Thus from reported data and from the 
personal experience, some conclusions can 
be made: 
• FK506 is steroid sparing and decreases the 
need for OKT3 
• When comparing FK506 and CyA for 
liver disease recurrence, both agents have 
equivalent outcome in HBV, HCV and 
tumour patients. 
• The efficacy of new combinations, such as 
FK506 + MMF or Cyclosporin A + Rapa 
should be assessed. 
The other main area of research is the 
development of new strategies to induce or 
facilitate donor-specific tolerance. One of 
these strategies is simultaneous BM infusion 
and OlT. Are there any cffects llf this 
procedure on HBV or HCY recurrence after 
the transplant? There are no data on early 
stages, but at a late stage a drug-free status 
can be achieved or, at least, a low 
immunosuppressive status; this lowers the 
risk of recurrence and, ultimately, the risk of 
re-transplantation or death. 
After BMT x only, infused in HBV positive 
patients, there is no evidence of increased 
incidence of liver disease. Data from 3 major 
reports support the use of BM infusion 
simultaneously to OlT in hepatitis patients. 
Dr. Antonina Smedile on behalf of the 
Turin liver transplant group (Dr. Marzano, 
De Bernardi, Ghisetti, Brunetto, Torrani, 
Salizzoni) addressed the issue of a safe level 
of pre-transplant viraemia and that of anti-
viral prophylaxis in HBV transplants. 
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An important factor predicting the rate of 
HBV recurrences is HBY-DNA quanti tat ion 
prior to OlT. Using a PCR-based assay for 
HBV- DNA detection in candidates 
undergoing OlT, it was demonstrated that 
the risk of re-infection was lower « 17%) in 
those testing peR-negative before surgery. 
This evidence has prompted the use of 
available anti-viral therapy as a prophylactic 
measure, prior to OlT, to abate levels of 
viraemia below peR sensitivity for the 
prevention of HBV recurrence. Dr. Smedile 
reported the experience in Turin between 
1994-1997, in a subgroup of viraemic 
candidates with chronic HBV infection 
treated before OlT with gancyclovir, ARA-
AMP or lamivudine followed by standard 
HBIg administration. Patients' features and 
schedule of treatment with nucleoside 
analogues are reported in Figures 2, 3. 
In the period 1994-1996, 16 patients were 
treated with gancyclovir and ARA-AMP 
prior to OlT (12 gancYclovir, 4 ARA-
AMP); 4 died after surgery and 12 are alive 
with a mean follow-up of 24 months (range 
13-33 mo). In all treated patients the levels 
of viraemia before surgery were between 103 
-10 7 genome/ml; serum HBV- DNA de-
creased after therapy by 1-2 log; at the time 
of transplantation 5 patients tested weakly 
positive by peR for HBV-DNA, 6 were 
PCR-negative and in 5 viraemia had 
decreased but was still strongly positive by 
peR. 
HBV re-infection occurred in 3 patients 
(gancyclovir 2/8 25%; ARA-AMP 1/4 
25%); the time of recurrence was between 2-
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4 months after OlT. All 3 re-infected 
patients had a symptomatic hepatitis which 
was treated with lamivudine (100- 300 mg); 
in all, HBY-DNA cleared in two months 
and the acute hepatitis evolved to chronic 
hepatitis. 
In the period 1996-1997, 21 patients in the 
waiting list have been treated with lami-
vudine 100-300 mg/day, obtaining a 
sustained suppression of viral replicaton; 10 
patients (3 HBeAg positive) who became 
peR HBV DNA negative under therapy, 
were transplanted. None had a recurrence of 
HBV after a medium follow-up of 6 months 
(range 6-12 mo). lamivudine was well 
tolerated prior to OlT in decompensated 
cirrhosis and during the therapy of recurrent 
hepatitis. No adverse effects were noted in 
long-term treated transplants. 
These data confirm the concept that HBV 
viraemia influences the recurrence of hepa-
tits B in the graft; the risk is proportional to 
the level of viraemia and significantly 
diminishes with virus charges below 104 gen 
Eq/ml. Given pre-OlT, new nucleosides of 
recent development, such as lamivudine, are 
effective in decreasing the viral load and no 
re-infection was seen in the Turin series. 
However, larger studies in patients with 
chronic hepatitis B in the Far East treated 
with lamivudine, have reported a 10% of 
drug resistance with emergence of 
lamivudine-resistant HBV variants. Similar 
experience was reported in England in 
patients treated with lamivudine prior to 
OlT without HBIg prophylaxis after surgery. 
The use of prophylactic anti-viral therapy 
• • • 
• • • 
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patients 
Figure 2. HBV-DNA before and after therapy with LamivucUnc 
• Hm-,DNAhciort'thcrapy: • HBV-DNAajrcrrhcra(lv: & HBcAg 
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Figure 3. HBV-DNA before and after therapy with ganciclovir and Lactosaminated ARA·AMP 
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comhined with standard HBIg protection 
after OlT remains an open question since 
there is no clear evidence that HBV 
recurrence can he prevented with antiviral 
drugs alone. Dr. Starzl commented that 
there is indeed a tremendous penalty for 
HBV patients. In these patients, therapy 
with interferon may increase the risk of 
rejection. This, however, may he compen-
sated hy increasing immunosuppression; 
interestingly, the overall risk of liver 
rejection under IFN therapy in liver 
transplants is much less consistent than in 
kidney transplants. 
Transplantation for chronic Delta 
Hepatitis 
Liver transplantation is a valid therapeutic 
measure fur the therapy of decompensated 
delta cirrhosis. Delta hepatitis is an 
uncommon cause of liver transplantation in 
the United States hut represents a large 
proportion of transplants candidates in Italy 
of 27 patients who received short-term HBig 
prophylaxis against HBV or no prophylaxis 
at alL 22 (81 %) became re-infected with 
HOV, but only II (I4 l){1) were also re-
infected with HBV and had a HOV relapse. 
Treatment of recurrent delta hepatitis has 
heen unsatisfactory. Various therapies 
targeted to HBV have heen tried without 
success. However, the recurrence of hepatitis 
after transplantation for chronic delta 
hepatitis is less frequent than for chronic 
hepatitis B, the reason being that delta 
hepatitis cannot recur unless hepatitis B also 
recurs. As a consequence prevention of 
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HBV recurrence using passive immuno-
prophylaxis has also heen efficacious in the 
prevention of HOV infection. The re-
infection rate, after the introduction of 
standard HBlg prophylaxis against HBV, has 
diminished from 67 to 12-9% in two larger 
series studied in Italy and France. Thus, the 
long-term prophylaxis with immuno-
globulins against HBsAg is highly effective. 
In the Turin liver transplant program 45 
patients were transplanted for HliV 
cirrhosis. 
The characteristics of the patients are 
reported in Tahle 5. The clinical analysis 
demonstrated that there was in most 
reinfected patients an early HOV reinfection 
persisting at low levels and causinL: no 
hepatic damage. When HBV infection 
recurred, HOV increased exponentially and 
caused clinical disease. These evidences 
were recently revisited using sensitive peR-
assays to study the subsequent appearance of 
HOV/HBV nucleic acids in serum and liver 
,)f re-infected transplants. This analysis 
clearly demonstrated that there is a strict 
and interfering influence of HBV in the 
final appearance of liver damage in the graft. 
Table 5. OLT HDV patients in Turin 
Male/female 
Mean age (yrs) 
Median follow-up 
Post operative deaths 
HOY recurrence ( n O pts) 
27/13 
41 (23-56) 
43 (6-106) 
4 
6 
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MoreO\'er, the presence of nucleic acids 
(HDV RNA in 3; HDV-RNA/HBV-DNA in 
2 ) inn (l r e - i n fe c ted pat i c n t sun d e r 
permanent immunoprophylaxis raises douhts 
on the hypothesis to stop HBlg in this 
category of patients. 
There were 4 patients who developed 
chronic active hepatitis (CAH) and 2 who 
developed an histologic cirrhosis. The 8 
years survival curve according to Kaplan 
Mayer was excellent; 98% of patients are 
alive and well. 
In conclusion, liver transplantation for HOV 
hepatitis is one of the hetter indications for 
viral cirrhosis. Considering the maximum 
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peak of HOV disease expression in the early 
70-805 in North Italy and the persistence of 
HOV infection in Southern regions of the 
country, it is likely that more cases of HOV 
cirrhosis will require OlT in the next future. 
The long-term outcome of liver trans-
plantation for HOV cirrhosis, since the 
introduction of permanent HBIg prophylaxis 
looks very good. Results are also promising 
even for those few candidates with 
concomitant HBY replication; they are 
likely to benefit from anti-viral therapy with 
nucleoside analogues to inhihit HBV 
replication prior to surgery. 
M. Ri::etto et al. 
